Special Issue "Drug-Induced Diseases in the Elderly"
A special issue of Medicines (ISSN 2305-6320).
Deadline for manuscript submissions: 31 May 2021.
Interests: dementia; cognitive aging; neuroinflammation; neurodegeneration; comprensive geriatric assessment
Interests: rheumatic inflammatory diseases; elderly patients; drug-induced diseases; elderly-onset rheumatic diseases; polymyalgia rheumatica; conventional and non-conventional therapies in rheumatic patients; disease-modifying anti-rheumatic drugs; glucocorticoids; cronotherapy
It is common knowledge that medicines may induce or worsen several diseases. In some cases, drug-induced diseases are characterized by clinical and/or laboratory distinctive findings that are different from those of the correspondent "primary" diseases. In this sense, drug-induced lupus erythematosus (DILE) is paradigmatic. The use of assessment scales for adverse drug reactions (ADRs) such as the scale proposed in 1981 by Naranjo et al. is widely recommended in the published literature to avoid a deductive methodological approach. On the other hand, tardive syndromes may represent ADRs for which the use of the Naranjo’s scale or other different assessment scales may be difficult and critical. Finally, gender pharmacology, pharmacogenetics, and pharmacogenomics—when available—may provide essential information. In the elderly patients, polypharmacology has specific effects, often absent in other age groups, so that the role of over-the-counter products is by no means secondary. Moreover, age-related changes are possible both in pharmacodynamics and in pharmacokinetics.
The purpose of this Special Issue of Medicines is to explore all aspects of the wide world of drug-induced diseases in the elderly. We invite all colleagues to submit their research or review manuscripts on this important topic.
Dr. Alberto Castagna
Dr. Ciro Manzo
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- adverse drug reaction
- assessment scales
- case reports
- case series
- drug–drug interactions
- drugs and over-the-counter products interactions
- gender pharmacology